Hester Biosciences Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Hester Biosciences announced that the Board of Directors of the Company at its meeting held on 15 May 2026, inter alia, have recommended the final dividend of Rs 11 per equity Share (i.e. 110%) , subject to the approval of the shareholders.

Net profit of Hester Biosciences rose 1138.76% to Rs 15.98 crore in the quarter ended March 2026 as against Rs 1.29 crore during the previous quarter ended March 2025. Sales rose 22.19% to Rs 100.11 crore in the quarter ended March 2026 as against Rs 81.93 crore during the previous quarter ended March 2025.

For the full year,net profit rose 102.40% to Rs 55.64 crore in the year ended March 2026 as against Rs 27.49 crore during the previous year ended March 2025. Sales rose 6.91% to Rs 332.60 crore in the year ended March 2026 as against Rs 311.10 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Hester Biosciences will hold a meeting of the Board of Directors of the Company on 15 May 2026.

The company?s currently holds around 54.81% stake in Texas Lifesciences.

Texas Lifesciences had recorded a turnover of Rs 28.59 crore and its net worth was Rs 13.41 crore in FY2024-25.

Offering details of this transaction, the company stated that the 43.81% shareholding of Hester will be transferred to Ticop Life, an entity affiliated to the existing promoter shareholders of TLPL.

Hester will continue to do business with TLPL and maintain an 11% equity stake in the company.

The company expects to conclude this transaction within a period of three months from the date of this agreement. It will receive a consideration of Rs 9.2 crore as a part of this transaction.

Hester Biosciences Limited is one of the India?s leading animal health company, manufacturing vaccines and health products. It is the second largest poultry vaccine manufacturer, with approximately 35% market share in India.

The company had reported 24.79% fall in consolidated net profit to Rs 8.77 crore despite a 22.46% increase in revenue to Rs 77.42 crore in Q3 FY26 as compared with Q3 FY25.

The scrip fell 0.17% to currently trade at Rs 1450.00 on the BSE.

Powered by Capital Market - Live News